Biotech Roundup: Compugen, Nxera Milestone Payments; Insmed Seeks $650M Offering

- Compugen and Nxera have disclosed milestone payments.
- Insmed aims to raise $650 million through an offering.
- Celcuity and Weave Bio are also mentioned in the news.
- Compugen received a milestone payment from AstraZeneca.
- Novo Nordisk Foundation plans to reinvest profits into regenerative medicines.
- The FDA expanded the use of BMS's blood cancer drug Breyanzi.
- Novartis ended development of a KRAS drug.
- A clinical labs trade group is suing to block the FDA's LDT rule.